Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity

Eli Lilly was the top contributor to relative returns in Q4 at a 1.8% position. Advanced Micro Devices was the top detractor with a 0.7% position. The fund initiated new positions in Johnson & Johnson (1.0%) and also initiated a position in AMD during the quarter.

Analysis

Large-cap pharma and diversified health care (LLY / JNJ) benefit from a macro backdrop where defensive allocations and buttoned-up earnings materially outperform cyclical tech on shorter horizons; second-order beneficiaries include CDMOs and antibody-component suppliers whose revenue growth lags but is stickier when a lead product sequence is stable. Semiconductor suppliers (AMD) face a classic inventory-cycle squeeze that feeds through to TSMC wafer allocation, memory vendors and test/assembly partners — a prolonged correction shaves fab utilization and compresses semi-cap equipment orders 2-4 quarters after revenue inflection.

Key risks are asymmetric by horizon. Over days–weeks, flows and quant de-risking can cause 8–12% swings in semis vs pharma; over months, data readouts, pricing regulation or biosimilar entry can remove 10–30% of pharma premium, while a sudden reacceleration in AI/data-center demand could restore 20–40% of semi market cap within 6–12 months. Watch near-term catalysts (earnings, guidance, major clinical readouts, Nvidia data-center cadence) that would flip positioning quickly.

Consensus is treating the semiconductor move as secular when much is cyclical: if channel destocking is the driver, downside is finite and a stacked options position can capture a convex recovery. Conversely, pharma complacency on litigation/regulatory revisions is underappreciated; a targeted hedge for large-cap pharma allocations is prudent. The highest-conviction tactical play is a defensive tilt (healthcare) financed by directional or volatility sells into semiconductors, sized to withstand a 20–30% idiosyncratic move against either leg.

Key Decisions for Investors

• Buy LLY equity (initiate or add) sized to a 2–3% portfolio weight and sell 6–8 week 3–5% OTM calls to harvest premium while retaining upside exposure; target 6–12% total return over 3–6 months, stop-loss if stock falls 12% from entry (event risk: trial/regulatory news).
• Establish a pair: long JNJ (3–6 month horizon) vs short AMD (equal dollar notional) to capture defensive vs cyclical spread; size to target 300–500bps relative outperformance if macro softens, unwind within 3–6 months or on AMD inventory normalization signals (TSMC utilization, channel destock data).
• Tactical AMD hedge/short: buy a 3-month ATM put or put spread (risk-defined) representing ~1% portfolio risk to protect against a near-term earnings/guidance downside; target payoff if AMD moves -15–25% and close on signs of stabilized sell-through or order restarts.
• Contrarian NVIDIA/AMD optionality: if willing to back the AI recovery, buy a 9–12 month AMD OTM call spread (cost-limited) sized small (0.5–1% portfolio risk) to capture >2x upside if data-center demand accelerates, funded by shorter-term volatility sells on other non-core names.